MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Medpace Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 22, 2026
$619.66+1.19 (+0.19%)
Close on Oct 19, 2026
- Market cap
- $17.69B
- P/E (TTM)
- 36.3
- Dividend yield
- –
Medpace Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other | $905.69M | $834.50M | $744.96M | $618.01M | $543.49M | $501.92M | $457.54M | $433.70M | $412.08M | $393.64M | $376.84M | $355.31M | 32.6% | +66.6% |
| Metabolic | $799.16M | $778.35M | $747.59M | $719.84M | $692.12M | $666.52M | $651.24M | $631.80M | $616.21M | $600.34M | $587.10M | $562.57M | 28.7% | +15.5% |
| Oncology | $386.25M | $406.03M | $408.55M | $423.48M | $424.45M | $418.82M | $431.38M | $438.73M | $437.52M | $426.14M | $404.84M | $374.49M | 13.9% | -9.0% |
| Cardiology | $301.87M | $280.14M | $254.84M | $230.88M | $207.35M | $192.74M | $181.98M | $172.40M | $174.29M | $165.50M | $160.06M | $157.54M | 10.8% | +45.6% |
| Central Nervous System | $238.75M | $237.35M | $239.37M | $234.64M | $230.98M | $233.10M | $230.45M | $223.73M | $212.28M | $202.71M | $193.69M | $187.52M | 8.6% | +3.4% |
| AVAI | $150.56M | $141.89M | $134.94M | $131.53M | $133.39M | $143.49M | $156.46M | $170.51M | $177.67M | $174.48M | $163.31M | $144.11M | 5.4% | +12.9% |
| Revenue net | – | – | – | – | – | – | – | – | – | – | $1.89B | $1.78B | – | – |
By region
From the segment and revenue-disaggregation notes of Medpace's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.